healthcare professionals
Product areas
Consumer health
Pain relief
Cough & cold
Gastro
Other
Specialty Pharma
Dermatology
Woundcare
Womens health
Urology
Obesity
Medical Nutrition
Protein
Glycogen Storage Disease (GSD)
Fat Metabolism
Renal
Nutritional support
Ketogenic Diet (KD)
Branded generics
Cardiology
Antibiotics
Business development
Business Model
Quality
Local knowledge
Our partners
Investors
Stock exchange news
Navamedic share
Annual General Meeting
Top 20 shareholders
Financial results
Annual reports
Prospectus
Financial calendar
Corporate governance
About
Contact
Vacant positions
Press
Management
Board of directors
EFPIA Disclosure code
Product areas
Consumer health
Pain relief
Cough & cold
Gastro
Other
Specialty Pharma
Dermatology
Woundcare
Womens health
Urology
Obesity
Medical Nutrition
Protein
Glycogen Storage Disease (GSD)
Fat Metabolism
Renal
Nutritional support
Ketogenic Diet (KD)
Branded generics
Cardiology
Antibiotics
Business development
Business Model
Quality
Local knowledge
Our partners
Investors
Stock exchange news
Navamedic share
Annual General Meeting
Top 20 shareholders
Financial results
Annual reports
Prospectus
Financial calendar
Corporate governance
About
Contact
Vacant positions
Press
Management
Board of directors
EFPIA Disclosure code
Financial results
Stock exchange news
Navamedic share
Annual General Meeting
Top 20 shareholders
Financial results
Annual reports
Prospectus
Financial calendar
Corporate governance
Financial results
2019
2020
2021
Q1
Q1 Presentation 2019
Q2
Q2 & Half Year Presentation 2019
Navamedic ASA - Second quarter 2019 presentation
Q3
Q3 Presentation 2019
Q4
Q4 Presentation 2019
Q1
Webcast Q1
Q1 Presentation 2020
Q2
Webcast Q2
Navamedic Q2 2020 Presentation
Navamedic Q2 and 1H 2020 Report
Q3
Webcast Q3
Navamedic Q3 2020 Presentation
Q4
Webcast Q4
Navamedic Q4 2020 Presentation
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
Ok
Privacy policy
